Compare EPSN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | MGNX |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 220.6M |
| IPO Year | 2018 | 2013 |
| Metric | EPSN | MGNX |
|---|---|---|
| Price | $5.66 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 177.0K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.19 |
| P/E Ratio | $281.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.20 | $1.30 |
| 52 Week High | $6.65 | $5.08 |
| Indicator | EPSN | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 48.12 |
| Support Level | $5.57 | $1.49 |
| Resistance Level | $5.96 | $4.55 |
| Average True Range (ATR) | 0.21 | 0.33 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 75.97 | 27.49 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.